Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated May 04, 2026, titled "OneSource Supports Second Generic Semaglutide Approval in Canada-Enables commercialisation for the first two entrants in the world s second-largest semaglutide market".
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
OneSource Specialty Pharma announced that its partner Orbicular, along with its Canadian front-end partner, received approval from Health Canada for a generic version of Ozempic® (semaglutide injection). This is the second generic semaglutide approval in Canada, making OneSource's partners the first generic entrants in this market. OneSource served as the manufacturing partner, providing end-to-end manufacturing capabilities from its US FDA-approved facility in Bengaluru. The approval follows a recent tentative approval in the United States also supported by OneSource, reinforcing the company's growing presence in complex peptide-based injectable programs.
Positive development for OneSource as it enables commercialization in Canada's semaglutide market (the world's second-largest), builds on momentum from US and India approvals, and strengthens the company's position as a global CDMO partner for complex pharmaceutical products.